Palvella Therapeutics (NASDAQ:PVLA) Earns “Buy” Rating from HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $38.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 166.67% from the stock’s current price.

Separately, Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating for the company.

Palvella Therapeutics Stock Down 3.3 %

PVLA opened at $14.25 on Friday. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32. The stock has a market capitalization of $18.81 million, a P/E ratio of -1.18 and a beta of 0.67.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the acquisition, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.39% of the company’s stock.